Director of Policy and External Affairs Justin Nordhorn discussed the background, intent, and changes requested in draft legislation on “psychotropic” and “impairing” cannabis compounds.
Industry, academic, and agency representatives brought lawmakers up to speed on CBD product research and policy development in Washington state.
WSLCB Director Rick Garza shared new details about the background, leadership, and advocacy of CANNRA as he encouraged traffic safety officials to affiliate with the organization.
Staff described outreach to a U.S. Senator, participation in the spring meeting of a prominent cannabis organization, and planned revisions to the scope of rulemaking on synthesized cannabinoids.
Details of a board member’s discussion with state counsel on synthesized delta-9-THC led to conversation about the policy statements and agency regulatory powers beyond rulemaking.
Members asked about the potential to include consideration of synthesized delta-9-THC in open rulemaking and had a lengthy discussion on the tone of official statements on the matter.
Amidst long solstice days after a week of high temperatures, important decisions about the future of the Washington state cannabis industry were under way - and more heat was expected.
During a hearing on tier 1 canopy and public comment, licensees and citizens spoke to perceived limitations of the Joints for Jabs program, hemp biomass, and market structure.
The board chair responded to public comments on incentivizing coronavirus vaccination, the safety of converting hemp distillate into THC, and inaction towards business normalization.
The board gave permission to start a new rulemaking project around “THC Compounds Other than Delta-9” and heard “frustrations” of a prominent cannabis association lobbyist.